1 recruiting, 1 suspended. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Recruiting 1, Suspended 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow IDP-023: new trials by email Literature Review of IDP-023 trials Research Report on IDP-023
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis IDP-023, Ocrelizumab, Interleukin-2 - Multiple Sclerosis, Primary Progressive Multiple Sclerosis (PPMS) | Phase 1 | Suspended | Indapta Therapeutics, INC. | 34 | 2026-06-30 | 2025-04-30 |
| IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers IDP-023, Rituximab, Daratumumab - NHL, Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | Indapta Therapeutics, INC. | 128 | 2023-10-25 | 2025-06-03 |
Autoimmune Diseases (1) · Autoimmune Diseases of the Nervous System (1) · Demyelinating Autoimmune Diseases, CNS (1) · Demyelinating Diseases (1) · Hematologic Neoplasms (1) · Immune System Diseases (1) · Lymphoma, Non-Hodgkin (1) · Multiple Myeloma (1) · Multiple Sclerosis (1) · Multiple Sclerosis, Chronic Progressive (1) · Nervous System Diseases (1)
Indapta Therapeutics, INC. (2)
United States (2)